Patents Assigned to Eisai R&D Management Co., Ltd.
  • Patent number: 10428140
    Abstract: It is intended to provide an anti-EphA4 antibody or an EphA4-binding fragment thereof which is capable of binding to EphA4 and inhibiting the binding between EphA4 and its ligand, and a pharmaceutical composition comprising the anti-EphA4 antibody or the EphA4-binding fragment thereof as an active ingredient. A mouse anti-EphA4 antibody having binding affinity for EphA4 was obtained, and the sequences of complementarity-determining regions (CDRs) of the mouse anti-EphA4 antibody were identified. This allowed for preparation of a humanized antibody comprising the CDR sequences of the mouse anti-EphA4 antibody in heavy chain variable region and light chain variable region.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: October 1, 2019
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Ryota Taguchi, Toshio Imai, Eiji Inoue, Akio Yamada, Aki Nakatani, Toshifumi Hirayama, Yuichi Ono, Shunsuke Ito
  • Publication number: 20190276560
    Abstract: Methods and combination therapies for treating, preventing, and/or delaying the onset and/or development of Alzheimer's disease using an anti-A? protofibril antibody (such as, for example, BAN2401) and N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide and/or a pharmaceutically acceptable salt thereof (Compound X) are provided.
    Type: Application
    Filed: October 26, 2017
    Publication date: September 12, 2019
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Andrew SATLIN, Tatsuto FUKUSHIMA
  • Publication number: 20190275067
    Abstract: The present invention is directed to methods for treating ebola virus infections or Marburg virus infections comprising administering to a subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 14, 2017
    Publication date: September 12, 2019
    Applicants: EISAI R&D MANAGEMENT CO., LTD., THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Alexander BUKREYEV, Fabian GUSOVSKY, Patrick YOUNAN, Michael EVERSON
  • Patent number: 10406126
    Abstract: The present invention provides a compound represented by formula (1): or pharmaceutically acceptable salt thereof, wherein X and Y are the same or different from each other and represent a hydrogen atom, a halogen atom, a C1-6 alkyl group, or a C1-6 alkoxy group, wherein the C1-6 alkoxy group may be substituted with a C1-6 alkoxy group, and Z and W are the same or different from each other and represent a hydrogen atom, a halogen atom, or a C1-6 alkyl group.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: September 10, 2019
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Keigo Tanaka, Tasuku Ishida, Masayuki Miyano, Raku Shinkyo
  • Patent number: 10407439
    Abstract: The present invention relates to stereochemically defined polypropionates and methods for preparing and using the same. The stereochemically defined polypropionates may be useful in the synthesis of natural products and/or natural product-like libraries.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: September 10, 2019
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Francis G. Fang, Hyeong-Wook Choi, Silvio Campagna, Steven Mathieu
  • Patent number: 10407393
    Abstract: Provided is a compound represented by formula (IV) or a salt thereof, wherein the content of the compound represented by formula (I) is 350 ppm by mass or less.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: September 10, 2019
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Taiju Nakamura, Taichi Abe, Yusuke Miyashita, Hirofumi Kuroda, Yusuke Ayata, Atsushi Akao
  • Publication number: 20190263927
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and eribulin or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of urothelial cancer.
    Type: Application
    Filed: October 13, 2017
    Publication date: August 29, 2019
    Applicants: Merck Sharp & Dohme Corp., Eisai R&D Management Co., Ltd.
    Inventor: Martin S. OLIVO
  • Patent number: 10357495
    Abstract: Embodiments herein are directed to topical formulations of a compound represented by the formula (I), salt, metabolite, prodrug, or hydrate thereof along with a solvent, and a base. The compound is a PDE4 inhibitor and the topical formulations may be used to treat dermatological conditions such as, but not limited to, atopic dermatitis, seborrheic dermatitis, alopecia, contact dermatitis, psoriasis, urticaria, eczema, burns, sunburn, pancreatitis, hepatitis, lichen planus, scleritis, scleroderma, dermatomyositis, itching associated with any of the preceding conditions or a combination thereof.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: July 23, 2019
    Assignees: DERMAVANT SCIENCES GMBH, EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Ambrish Vyas, Seiji Takemoto, Yoshihiro Akimoto
  • Patent number: 10358485
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: July 23, 2019
    Assignees: Eisai R&D Management Co., Ltd., UCL Business PLC
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • Publication number: 20190218180
    Abstract: The present invention provides a cationic lipid which is able to be used for nucleic acid delivery to the cytoplasm. A cationic lipid according to the present invention is, for example, a compound represented by formula (1a) or a pharmaceutically acceptable salt thereof. (In formula (1a), each of L1 and L2 independently represent an alkylene group having 3-10 carbon atoms; each of R1 and R2 independently represent an alkyl group having 4-22 carbon atoms or an alkenyl group having 4-22 carbon atoms; X1 represents a single bond or —CO—O—; and ring P represents one of formulae (P-1) to (P-5).)(In formulae (P-1) to (P-5), R3 represents an alkyl group having 1-3 carbon atoms.
    Type: Application
    Filed: June 22, 2017
    Publication date: July 18, 2019
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Yuta Suzuki, Yoshinori Takahashi
  • Publication number: 20190201399
    Abstract: In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.
    Type: Application
    Filed: January 23, 2019
    Publication date: July 4, 2019
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Margaret MOLINE, Gina PASTINO, Yurie AKIMOTO, Yasuhiro ZAIMA, Nobuya SUZUKI, Nobuo YOSHIDA
  • Publication number: 20190185432
    Abstract: Provided is a compound represented by formula (IV) or a salt thereof, wherein the content of the compound represented by formula (I) is 350 ppm by mass or less.
    Type: Application
    Filed: December 21, 2018
    Publication date: June 20, 2019
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Taiju Nakamura, Taichi Abe, Yusuke Miyashita, Hirofumi Kuroda, Yusuke Ayata, Atsushi Akao
  • Patent number: 10322192
    Abstract: Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: June 18, 2019
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Earl F. Albone, Xin Cheng, Daniel W. Custar, Keiji Furuuchi, Jing Li, Utpal Majumder, Toshimitsu Uenaka
  • Publication number: 20190175598
    Abstract: Provided herein is a combination therapy useful for the treatment hepatocellular carcinoma and/or intrahepatic cholangiocarcinoma. The combination comprises an EGFR4 inhibitor and a CDK 4/6 inhibitor.
    Type: Application
    Filed: August 23, 2017
    Publication date: June 13, 2019
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Anand Selvaraj, Peter Smith
  • Patent number: 10316040
    Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: June 11, 2019
    Assignee: Eisai R&D Management Co., LTD.
    Inventors: Wanjun Zheng, Xiaojie Zhu, Hong Du, Maarten Postema, Yimin Jiang, Jing Li, Robert Yu, Hyeong-wook Choi, Jaemoon Lee, Frank Fang, Daniel Custar
  • Patent number: 10308661
    Abstract: The invention provides methods for the synthesis of a halichondrin macrolides through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Homer-Wadsworth-Emmons olefination), catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic macrolide. The invention also provides compounds useful as intermediates in the synthesis of a halichondrin macrolides and methods for preparing the same.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: June 4, 2019
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Francis G. Fang, Dae-Shik Kim, Hyeong-Wook Choi, Charles E. Chase
  • Publication number: 20190144419
    Abstract: The present invention provides salts of (E)-N,N-dimethyl-4-((2-((5-((Z)-4,4,4-trifluoro-1-(3-fluoro-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)pyridin-2-yl)oxy)ethyl)amino)but-2-enamide represented by the formula I and acids, and crystals thereof, possessing a potential to be used as drug substance in pharmaceuticals.
    Type: Application
    Filed: November 27, 2017
    Publication date: May 16, 2019
    Applicant: Eisai R&D Management Co., Ltd.
    Inventor: Keiko Onuma
  • Patent number: 10273310
    Abstract: Provided herein are methods for generating conjugated immunoglobulins, the method comprising: decapping a cysteine at amino acid position 80 (“Cys80”) in a light chain variable region of an immunoglobulin, wherein the immunoglobulin comprises a heavy chain variable region and the light chain variable region; and conjugating a thiol-reactive compound to the Cys80, wherein the thiol-reactive compound comprises a thiol-reactive group. Antigen-binding molecules and methods for generating the same, immunoglobulins as well as nucleic acid molecules encoding the immunoglobulins and host cells comprising the nucleic acid molecules, conjugated immunoglobulins, and light chain variable regions for use in a conjugated immunoglobulin are also provided.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: April 30, 2019
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Luigi Grasso, Jared Spidel, James Bradford Kline, Earl Albone
  • Publication number: 20190117640
    Abstract: Provided herein is a combination of agents for reducing cell viability and/or cell proliferation. The combination comprises an FGFR4 inhibitor and an EGFR inhibitor.
    Type: Application
    Filed: May 9, 2017
    Publication date: April 25, 2019
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Anand Selvaraj, Peter Smith
  • Publication number: 20190111043
    Abstract: The present invention provides a therapeutic agent for bile duct cancer comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: December 19, 2018
    Publication date: April 18, 2019
    Applicants: NATIONAL CANCER CENTER, Eisai R&D Management Co., Ltd.
    Inventors: Tatsuhiro SHIBATA, Yasuhito ARAI, Kenichi NOMOTO, Tomio NAKAMURA, Akihiko TSURUOKA, Saori MIYANO